NCT07437963 Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT06896916 Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Status RECRUITING Phase PHASE1
NCT06785415 Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma Status RECRUITING Phase PHASE1/PHASE2
NCT06762769 Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma Status RECRUITING Phase PHASE2
NCT06518551 Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM Status RECRUITING Phase PHASE1/PHASE2
NCT06465316 Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma Status RECRUITING Phase PHASE1
NCT06348108 Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Status RECRUITING Phase PHASE1
NCT06232044 Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma Status RECRUITING Phase PHASE1/PHASE2
NCT06216158 Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma Status RECRUITING Phase PHASE3
NCT06215118 A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) Status RECRUITING Phase PHASE1
NCT06179888 Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma Status RECRUITING Phase PHASE2
NCT06121843 A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma Status RECRUITING Phase PHASE1
NCT06107738 Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma Status RECRUITING Phase PHASE2
NCT05899738 A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants Status COMPLETED Phase PHASE1
NCT05896228 Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma Status RECRUITING Phase PHASE2
NCT05827016 A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma Status RECRUITING Phase PHASE3
NCT05583617 A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma Status RECRUITING Phase PHASE1/PHASE2
NCT05560399 A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase EARLY_PHASE1
NCT05558319 NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide Status NOT_YET_RECRUITING Phase PHASE3